Valuation: Santhera Pharmaceuticals Holding AG

Market Cap 254M 317M 271M 232M 436M 30.29B 442M 3B 1.17B 15.22B 1.19B 1.16B 50.33B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 281M 351M 301M 258M 484M 33.6B 490M 3.33B 1.3B 16.88B 1.32B 1.29B 55.83B EV / Sales 2026 *
2.97x
EV / Sales 2027 * 2.38x
Free-Float
81.52%
Yield 2026 *
-
Yield 2027 * -
1 day+1.75%
6 months+9.93%
Current year+74.16%
Current year 15.63
Extreme 15.63
23.25
1 year 12.28
Extreme 12.275
23.25
3 years 9.4
Extreme 9.4
23.25
5 years 6.8
Extreme 6.8
26.3
10 years 6.8
Extreme 6.8
810.5
Manager TitleAgeSince
Chief Executive Officer 50 2026-07-14
Director of Finance/CFO 51 2025-02-23
Chief Operating Officer 55 2022-08-31
Director TitleAgeSince
Chairman 64 2022-06-29
Director/Board Member 58 2017-04-03
Director/Board Member 47 2023-06-26
Change 5-day change 1-year change 3-year change Capi.($)
+1.75%-.--% - - 317M
+2.39%+12.30%+77.22%+39.14% 376B
-0.07%+1.21%+24.84%-12.66% 70.02B
+1.93%+9.64%+51.05%+153.80% 12.28B
-1.85%-0.12%-2.05%-0.25% 8.49B
-3.24%-4.12%-13.89%-4.78% 4.73B
-1.32%-1.67%-27.62%+16.94% 4.43B
-8.11%-25.49%-20.13%+13.96% 3.2B
-3.37%-5.01%+5.84%+46.07% 2.67B
-2.76%-3.99%-14.59%-6.38% 2.11B
Average -1.47%-1.99%+8.96%+27.31% 53.81B
Weighted average by Cap. +1.74%+9.70%+64.31%+32.91%

Financials

2026 *2027 *
Net sales 94.7M 118M 101M 86.69M 163M 11.3B 165M 1.12B 436M 5.68B 444M 434M 18.78B 116M 144M 123M 106M 199M 13.79B 201M 1.37B 532M 6.93B 541M 530M 22.92B
Net income - -
Net Debt 27.7M 34.56M 29.6M 25.36M 47.59M 3.31B 48.21M 327M 128M 1.66B 130M 127M 5.49B 21.4M 26.7M 22.87M 19.59M 36.76M 2.55B 37.25M 253M 98.6M 1.28B 100M 98.07M 4.24B
Logo Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Employees
94
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
16.64CHF
Average target price
27.50CHF
Spread / Average Target
+65.26%

Quarterly revenue - Rate of surprise